Comparative Pharmacology
Head-to-head clinical analysis: PERIACTIN versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERIACTIN versus PROMETHAZINE DM.
PERIACTIN vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic